Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population The Copenhagen City Eye Study

Macrophages in neovascular age-related macular degeneration: friends or foes?

“…[1][2][3] In the United States alone, nearly two million individuals are afflicted with severe, end-stage AMD, and are legally blind. Seven million more have early stage AMD, or agerelated maculopathy, and are at high risk for developing advanced AMD.…”

Comparing Three Post-Op Regiments for Management of Inflammation Post Uncomplicated Cataract Surgery. “Are Steroids Really Necessary?”

“…Acquired cataract is the leading cause of blindness worldwide [13][14][15][16]. In the United States, cataract is the most common age-related eye disorder affecting approximately 22 million with a projected prevalence increasing to 30.1 million by the year 2020 [17,18].…”

Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage

“…In addition, about 30% of blindness in Western countries is caused by these diseases. [27][28][29] Current therapeutic strategies, such as ACE inhibitors, ang AT1R blockers, b-adrenergic receptor antagonists or antidiabetic agents only ameliorate but do not fully prevent or abolish cardiovascular end-organ damages. [30][31][32] The relevance of the (P)RR to these conditions is underlined by the impressive observations of Ichihara's group, which show that a decoy peptide corresponding to the handle region of prorenin named handle region peptide, which competitively inhibits prorenin binding to its receptor, attenuated the development and progression of hypertension-induced cardiac fibrosis, 33,34 and also completely inhibited the development of diabetic nephropathy in different rat models including AT1R knockout mice.…”